Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing ...

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Rule-breaking drug design takes advantage of CD36-dependent pathway A research team of scientists from Duke University School ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

Artificial intelligence models, pretrained on vast datasets, significantly outperformed a standard baseline model in ...

This paper investigates how isoform II of transcription factor RUNX2 promotes cell survival and proliferation in oral squamous cell carcinoma cell lines. The authors used gain and loss of function ...

a cancer biology researcher and professor in the Department of Pathology at Duke University School of Medicine. Most drug development focuses on tweaking molecules to improve their ability to slip ...

Compr Ophthalmol Update. 2007;8(1):1-14. The micronodular (. 15%) variant shows smaller tumor nodules (< 0.15 mm by definition) (Figure 1C) and has an increased tendency for subclinical extension.

Small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC) are the most deadly forms of lung cancer. The advent of numerous molecular targeted therapeutics, including immune ...